On Monday morning, 10 September 2018, Knowledge Ecology International (KEI) delivered the following oral statement at the World Health Organization’s (WHO) Informal Discussion of the Roadmap Report on Access to Medicines and Vaccines 2019–2023. The morning session provided UN agencies,… Continue Reading
On August 20, 2018, KEI filed comments in response to the US Federal Trade Commission’s hearings and public comment process to address, “Competition and Consumer Protection in the 21st Century.” The goal of the process is to examine, “whether broad-based… Continue Reading
On 12 June 2018 and 14 June 2018, the World Trade Organization (WTO) conducted a Trade Policy Review of Colombia. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place… Continue Reading
On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading
UPDATE: On Wednesday, 15 August 2018, WHO Director-General, Dr Tedros Adhanom Ghebreyesus provided a response to the open letter on the Roadmap on Access to Medicines and Vaccines 2019-2023. The Director-General’s response can be found here: WHO DG letter to… Continue Reading
The following is a question for the record from Senator Sherrod Brown, and a response from Alex Azar, in connection with Azar’s confirmation hearing. Questions for the Record January 9, 2018 Hearing to Consider the Nomination of Alex Azar to… Continue Reading
On 26 September 2018, the United Nations’ General Assembly will convene the first high-level meeting on tuberculosis; the theme of the meeting is “United to end tuberculosis: an urgent global response to a global epidemic”. In preparation for the United… Continue Reading
The new House democrats medicare negotiations bill represents a turning point, with broad support for using robust compulsory licensing authority to protect access if negotiations on prices break down. The press conference announcing the bill featured several Democratic members of… Continue Reading
The following are comments by the KEI on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to notice in the Federal Register, 83 FR 22692. Overall, the Blueprint is very weak, and won’t do much… Continue Reading